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Abstract
The development of drugs with different pharmacological properties appears to
be an innovative therapeutic approach for Alzheimer’s disease. In this article,
we describe a simple structural modification of AP2238, a first dual function
lead, in particular the introduction of the catechol moiety performed in order
to search for multi-target ligands. The new compound AP2469 retains anti-
acetylcholinesterase (AChE) and beta-site amyloid precursor protein cleaving
enzyme (BACE)1 activities compared to the reference, and is also able to inhibit
Ab42 self-aggregation, Ab42 oligomer-binding to cell membrane and subse-
quently reactive oxygen species formation in both neuronal and microglial cells.
The ability of AP2469 to interfere with Ab42 oligomer-binding to neuron and
microglial cell membrane gives this molecule both neuroprotective and anti-
inflammatory properties. These findings, together with its strong chain-breaking
antioxidant performance, make AP2469 a potential drug able to modify the
course of the disease.
Abbreviations
AChE, acetylcholinesterase; AIBN, azobisisobutyronitrile; Ab, b-amyloid peptide;
BACE1, beta-site amyloid precursor protein cleaving enzyme 1; BuChE, butyrylcho-
linesterase; CR, Congo red; DCFH-DA, 2′,7′-dichlorodihydrofluorescein diacetate;
DHE, dihydroethidium; EPR, electron paramagnetic resonance; MTT, 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NO, nitric oxide; ROS,
reactive oxygen species; TAA, total antioxidant activity; t-BuOOH, tert-butyl hydro-
peroxide; ThT, thioflavin T; TNF, tumor necrosis factor.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder of the brain associated with cognitive
impairment, memory loss, and changes in personality and
behavior, affecting a large portion of the aging popula-
tion. Considerable research is in progress to understand
the pathogenesis of the disease and find a cure.
Structural modifications in the brain have been identi-
fied as pathological hallmarks of AD, especially in regions
such as the cortex, basal forebrain nuclei, and hippocam-
pus (Selkoe 1993): synaptic loss, with drastic reduction in
the cholinergic tone, extracellular senile plaque, mostly
composed of aggregated b-amyloid peptide (Ab) and
intracellular neurofibrillary tangles, containing hyper-
phosphorylated Tau protein (Kowall 1999; Fine, 1999).
Recent experimental evidence has demonstrated that
neuronal exposure to very low concentrations of soluble
Ab oligomers can initiate neurophysiological changes
which are likely related to the synaptic dysfunction associ-
ated with AD. Ab is a proteolytic fragment derived from
the amyloid precursor protein, APP, which is processed
by the enzyme a-secretase, in physiological conditions, to
generate small and soluble peptides (Selkoe 1994; Hardy
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and Selkoe 2002). In the AD affected brain a second path-
way, known as the “amyloidogenic pathway”, is activated,
involving the sequential action of b-secretase (or beta-site
amyloid precursor protein cleavage enzyme [BACE1]) and
c-secretase, to generate two predominant Ab peptides,
either 40 or 42 amino acids in length, that are able to
aggregate into fibrils via soluble oligomers, leading, as
generally accepted, to neuronal toxicity. The therapeutic
approach should therefore try to decrease amyloid pro-
duction (Citron 2002; Guo and Hobbs 2006; Hills and
Vacca 2007), or block accumulation of misfolded peptide
aggregates (Talaga 2001; Estrada and Soto 2007).
Among the mechanisms involved in Ab-mediated neu-
rotoxicity, oxidative stress has been recognized as an early
event that plays a crucial role in the pathogenesis of AD.
Several studies showed that Ab generates various reactive
oxygen species (ROS), such as hydrogen peroxide, hydro-
xyl radical, and superoxide anion by directly interacting
with metals or indirectly by impairment of mitochondrial
activity (Bobba et al. 2010). In addition, the overload of
ROS induces accumulation of Ab establishing a vicious
circle that reinforces the oxidative stress with strengthen-
ing of oxidative damage at neuronal level (Tamagno et al.
2008).
Among the mechanisms involved in neuronal dysfunc-
tion and death, the accumulation of Ab peptide, in differ-
ent aggregation forms, including soluble oligomers and
insoluble fibrils, has also been linked to inflammation
responses in AD (Glass et al. 2010). It is recognized that
the microglial cells enhance and amplify neuronal damage
induced by Ab. It seems that this phenomenon, in turn,
induces more widespread damage – called reactive gliosis
– to neighboring neurons, resulting in a perpetuating
cycle of neuron death (Block et al. 2007). Ab has been
shown to activate microglial cells, in part by signaling
through toll-like receptors and glycosylation end prod-
ucts, which in turn induce the production of factors such
as nitric oxide (NO), ROS, proinflammatory cytokines,
chemokines and prostaglandins that promote neuronal
death (Glass et al. 2010).
Due to the complexity of this disease and the involvement
of different proteins in its progression, the modulation of a
single factor might not be sufficient to produce the desired
efficacy. Indeed, the current management of AD is
being reviewed and researchers are now turning to the
design of structures that could be able to simultaneously
interact with different targets involved in the pathogenic
process.
Our research group has been involved for several years
in the development of potential drugs for AD. In particu-
lar, AP2238 was the first dual binding site human acetyl-
cholinesterase (hAChE) inhibitor (Piazzi et al. 2003) for
which the simultaneous inhibition of the catalytic activity
and the proaggregatory action of AChE on amyloid-b
peptides was verified. Extensive structure–activity
relationship studies (Piazzi et al. 2007) have shown that
the structure of AP2238 is crucial for optimal activity.
Indeed, only the introduction of an ethyl group (AP2243)
instead of a methyl group on the basic nitrogen led to an
improvement in the anti-AChE activity without decreas-
ing the inhibitory potency on the AChE-induced Ab
aggregation.
In this article we describe a simple structural modifica-
tion of AP2243 (Fig. 1), leading to the introduction of
the catechol moiety. This structural modification was
based on the observation that catechol itself and catechol
derivatives such as dopamine and quercetin were recently
shown to possess antiaggregating properties (Di Giovanni
et al. 2010; Huong et al. 2010). In addition, quercetin
was also shown to inhibit BACE1 in both a cell-free sys-
tem and in neuronal cells (Shimmyo et al. 2008). Finally,
it is also well-known that catechols have antioxidant
activity, which might be beneficial in the treatment of AD
patients (Amorati and Valgimigli 2012; Valgimigli and
Pratt 2012). Therefore, the simple switch from the 6,7-
methoxy-2H-2-chromenone nucleus of AP2238 and
AP2243 to a catecholic one is expected to enlarge the
neuroprotective profile of the resulting compound and
obtain an effective multi-target directed ligand. In this
regard, we evaluated the neuroprotective profile of
AP2238 and AP2243 in terms of anticholinesterase and
antiaggregating activities, BACE1 inhibition, together with
antioxidant, neuroprotective, anti-inflammatory activity at
neuronal and microglial cell level.
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Figure 1. Drug design and synthesis of AP2469.
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Materials and Methods
Chemistry
General methods
Melting points were measured in glass capillary tubes on a
B€uchi SMP-20 apparatus (Milan, Italy) and are uncor-
rected. Direct infusion ES-MS spectra were recorded on a
Waters Micromass ZQ 4000 apparatus (Milan, Italy). 1H
NMR experiments were recorded on Varian VXR
300 MHz instruments (Palo Alto, CA). Chemical shifts are
reported in parts per million (ppm) relative to tetrameth-
ylsilane, and spin multiplicities are given as s (singlet), d
(doublet), t (triplet), dd (double doublet), dt (double trip-
let), m (multiplet) or br (broad). The results of the elemen-
tal analysis are within 0.4% of the theoretical values.
Chromatographic separations were performed on silica gel
columns (Kieselgel 40, 0.040–0.063 mm; Merck, Darms-
tadt, Germany) by flash chromatography. Compounds
were named following IUPAC rules as applied by Beilstein-
Institut AutoNom, version 2.1 (Frankfurt, Germany), a PC
integrated software package for systematic names in
organic chemistry. 3-{4-[(Benzylethylamino)-methyl]phe-
nyl}-6,7-dihydroxychromen-2-one (AP2469). A mixture of
AP2243 (Piazzi et al. 2007) (0.5 g) and 48% HBr (10 mL)
was heated to reflux for 3 h and then poured onto ice. The
aqueous layer was basified with NaHCO3, and extracted
with CH2Cl2. The combined organic layers were dried and
concentrated under reduced pressure to give a residue that
was converted in hydrochloride salt and crystallized from
MeOH/Et2O. AP2469 (55% yield) was obtained as a solid:
mp 198–199. 1H NMR: d 1.08 (t, 3H), 2.49–2.51 (m, 2H),
3.59 (s, 2H), 3.61 (s, 2H), 6.83 (s, 1H), 7.12–7.46 (m, 8H),
7.70 (d, 2H, J = 8.1 Hz), 7.95 (s, 1H). ES-MS (base) m/e:
402 (M + 1). Anal. (C25H24ClNO4), Calc.: C 68,57; H 5,52;
N, 3,20. Found: C 68,56; H 5,53; N, 3,23.
Inhibition of AChE and
butyrylcholinesterase
The method of Ellman et al. (1961) was followed. Five dif-
ferent concentrations of tested compounds were selected in
order to obtain inhibition of AChE or butyrylcholinesterase
(BuChE) activity comprised between 20% and 80%. In
detail, the following ranges of concentrations were screened:
AP2238, 6–320 nmol/L and 11600–116000 nmol/L for AChE
and BuChE, respectively; AP2243, 3–230 nmol/L and 3.4–
230 lmol/L for AChE and BuChE, respectively; AP2469,
2.60–29.0 lmol/L and 15.5–125 lmol/L for AChE and
BuChE, respectively; galanthamine 0.440–8.80 lmol/L
00 nmol/L and 4.50–91.50 lmol/L for AChE and BuChE,
respectively. The assay solution consisted of a 0.1 mol/L
potassium phosphate buffer pH 8.0, with the addition of
340 lmol/L 5,5′-dithio-bis (2-nitrobenzoic acid), 0.02 unit/
mL of human recombinant AChE or BuChE derived from
human serum (Sigma Chemical, Milan, Italy), and
550 lmol/L of substrate (acetylthiocholine iodide or buty-
rylthiocholine iodide, respectively). Compounds were added
to the assay solution and preincubated at 37°C with the
enzyme for 20 min before the addition of substrate. The
enzyme activity was determined by monitoring the increase
in absorbance at 412 nm over time. Assays were carried out
with a blank containing all components except AChE or
BuChE in order to account for nonenzymatic reaction. The
reaction rates were compared, and the percent inhibition
due to the presence of test compounds was calculated. Each
concentration was analyzed in triplicate, and IC50 values
were determined graphically from inhibition curves (log
inhibitor concentration vs. percent inhibition).
Inhibition of Ab42 self-aggregation
Antiaggregating properties of compounds AP2469 were
investigated in vitro by a thioflavin T (ThT)-based assay.
1,1,1,3,3,3-hexafluoro-2-propanol pretreated Ab1-42 sam-
ples (Bachem AG, Switzerland) were resolubilized with a
CH3CN/0.3 mmol/L Na2CO3/250 mmol/L NaOH (48.4/
48.4/3.2) mixture to have a stable stock solution ([Ab1-42]
= 500 lmol/L) (Bartolini et al. 2007). Experiments were
performed by incubating the peptide in 10 mmol/L phos-
phate buffer (pH = 8.0) containing 10 mmol/L NaCl, at
30°C for 24 h (final Ab concentration = 50 lmol/L) with
and without inhibitor. Volumes of 1.5 mmol/L stock
solutions were prepared by dissolving tested inhibitors in
methanol (c = 3.0 mmol/L); dilutions were prepared in
the assay buffer in order to achieve concentrations rang-
ing from 5 to 50 lmol/L in the final assay. Blanks con-
taining tested inhibitors and ThT were also prepared and
evaluated to account for quenching and interference
related to inhibitor fluorescence. To quantify amyloid
fibril formation, the ThT fluorescence method was used
(Naiki et al. 1991; LeVine 1993). After incubation, sam-
ples were diluted to a final volume of 2.0 mL with
50 mmol/L glycine-NaOH buffer (pH 8.5) containing
1.5 lmol/L ThT. A 300-sec-time scan of fluorescence
intensity was carried out (kexc = 446 nm; kem = 490 nm),
and values at plateau were averaged after subtracting the
background fluorescence of 1.5 lmol/L ThT solution and
of AP2469. The fluorescence intensities in the absence
and in the presence of the inhibitor were compared and
the percent inhibition was calculated.
Inhibition of BACE 1
AP2469 was evaluated for its ability to inhibit BACE1,
using a fluorescence resonance energy transfer assay.
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Purified Baculovirus-expressed BACE 1 (b-secretase) in
50 mmol/L Tris (pH = 7.5), 10% glycerol, and rhoda-
mine-derivative substrate (Panvera peptide) were pur-
chased from Invitrogen (Milan, Italy). Sodium acetate
and dimethyl sulfoxide (DMSO) were from Sigma
Aldrich. Purified water from Milli-RX system (Millipore,
Milford, MA) was used to prepare buffers and standard
solutions. Spectrofluorometric analyses were carried out
on a Fluoroskan Ascent multiwell spectrofluorometer
(kexc = 544 nm; kem = 590 nm) by using black microwell
(96 wells) Corning plates (Sigma Aldrich, Milan, Italy).
Stock solutions of the tested compounds were prepared
in DMSO and diluted with 50 mmol/L sodium acetate
buffer pH = 4.5. Specifically, 20 lL of BACE1 enzyme
(12.8 nmol/L, final concentration) were incubated with
20 lL of test compound for 60 min. To start the reaction,
20 lL of Panvera peptide (0.25 lmol/L, final concentra-
tion) was added to each well. The mixture was incubated
at 37°C for 60 min. To stop the reaction, 20 lL of BACE1
stop solution (sodium acetate 2.5 mol/L) was added to
each well. The spectrofluorometric assay was then
performed by reading the fluorescence signal at 590 nm.
The DMSO concentration in the final mixture main-
tained below 5% (v/v) guaranteed no significant loss of
enzyme activity. The fluorescence intensities with and
without inhibitor were compared and the percent inhibi-
tion due to the presence of test compounds was calculated.
The background signal was measured in control wells con-
taining all the reagents, except BACE 1 and subtracted.
The % inhibition due to the presence of increasing test
compound concentration was calculated by the following
expression: 100  (IFi/IFo 9 100) where IFi and IFo are
the fluorescence intensities obtained for BACE 1 in the
presence and in the absence of inhibitor, respectively. The
inhibition curve was obtained by plotting the % inhibition
versus the logarithm of inhibitor concentration in the
assay sample, when possible. The linear regression parame-
ters were determined and the IC50 extrapolated (GraphPad
Prism 4.0, GraphPad Software Inc.).
To demonstrate inhibition of BACE1 activity, a statine
peptide (H-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-[Statine
(3S,4S)]-Val-Ala-Glu-Phe-OH) derivative (Merck) was seri-
ally diluted into the reaction wells (IC50 = 0.018 lmol/L).
Determination of neuroprotective
and anti-inflammatory effects
Ab1-42 oligomers and Ab25-35 peptide preparation
for cytotoxicity assay
Ab1-42 and Ab25-35 peptides (Bachem AG) of the same lot
were first dissolved in hexafluoroisopropanol to 1 mg
mL1, sonicated, incubated at room temperature for 24 h
and lyophilized. The resulting unaggregated Ab1-42 and
Ab25-35 peptide film was dissolved with dimethylsulfoxide
and stored at 20°C until use. The Ab1-42 aggregation to
oligomeric form was prepared as previously described
(Maezawa et al. 2006). The morphology of oligomeric
Ab1-42 forms obtained was checked using transmission
electron microscopy as previously reported (Tarozzi et al.
2010a,b).
Cell cultures
Human neuronal (SH-SY5Y) and monocytic (THP-1) cells
were routinely grown in Dulbecco’s modified Eagle’ med-
ium and Royal Park Memorial Institute medium, respec-
tively, supplemented with 10% fetal bovine serum, 2 mmol/
L glutamine, 50 U mL1 penicillin, and 50 lg mL1 strep-
tomycin at 37°C in a humidified incubator with 5% CO2.
THP-1 cells are transformed human mononuclear cells that
have a range of properties similar to microglial cells and
represent a suitable cellular model for anti-inflammatory
effects (Klegeris and McGeer 2000; Yates et al. 2000).
Determination of Ab1-42 oligomer and Ab25-35
peptide-induced cytotoxicity
To evaluate the protective effects of compounds against
Ab1-42 oligomer- and Ab25-35 peptide-induced cytotoxic-
ity, the SH-SY5Y and THP-1cells were seeded in 96-well
plates at 3 9 104 cells/well and 5 9 104 cells/well, respec-
tively, incubated for 24 h and subsequently treated with
5 lmol/L of Ab1-42 oligomers and Ab25-35 peptide for 3 h
at 37°C in 5% CO2, in the presence or absence of various
concentrations of compounds (1–30 lmol/L). The cell
viability in terms of mitochondrial metabolic function
was evaluated by the reductionin 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) to
formazan as previously described (Tarozzi et al. 2010a,b).
The cellular reduction in MTT represents an indicator of
the initial events underlying the mechanism of Ab1-42 oli-
gomer and Ab25-35 peptide cytotoxicity. Briefly, the treat-
ment medium was replaced with MTT (5 mg/mL) in
phosphate-buffered saline (PBS) for 2 h at 37°C in 5%
CO2. After washing with PBS, the formazan crystals were
dissolved with isopropanol. The amount of formazan was
measured (570 nm, ref. 690 nm) using a spectrophotome-
ter (TECAN, GENios, Salzburg, Austria). The neuronal
viability is expressed as a percentage of control cells.
Determination of Ab1-42 oligomer binding
to the cell surface
SH-SY5Y and THP-1 cells were seeded in 96-well plates
at 5 9 103 cells/well and 5 9 104 cells/well, respectively,
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for 24 h. At the end of incubation, the medium was
changed with a fresh one with Ab1-42 oligomer (5 lmol/
L) and various compounds at 30 lmol/L for 30 min and
then washed twice with PBS. The residual Ab1-42 oligomer
cell complex was stained with 1 lmol/L of Congo red
(CR) in PBS for 20 min and measured with a spectropho-
tometer (TECAN, GENios) at 540 nm (bound CR). CR
values are reported as percent increases in treated cells
versus untreated cells.
Determination of antioxidant activity
Determination of intrinsic antioxidant activity
by electron paramagnetic resonance spectroscopy
The reaction between AP2469 or its methylated analogue
and peroxyl radical (ROO  ) was investigated by measur-
ing the kinetics of oxygen consumption during the azob-
isisobutyronitrile (AIBN)-initiated autoxidation of styrene
in chlorobenzene, whichs proceed via a well-established
radical-chain mechanism reported in equations 1–4
(Burton et al. 1985). In the presence of an antioxidant,
peroxyl radicals are trapped in reactions 5–6, the effi-
ciency of this process being dependent on the rate con-
stant of the reaction 5, kinh.
Initiator!Ri R (1)
R  þO2 ! ROO (2)
ROO  þRH!kp ROOHþ R (3)
ROO  þROO  !2kt non-radical products (4)
ROO  þAroH!kinh ROOHþ ArO (5)
ROO  þArO ! non-radical products (6)
During the inhibition period, the oxygen consumption
is given by equation 7, where kp is the propagation rate
constant of the oxidizable substrate (41 mol/L1s1 for
styrene) (Burton et al. 1985; Amorati et al. 2010, 2011)
and s the length of the induction period. The number of
peroxyl radicals trapped by each antioxidant molecule, n,
was experimentally determined from equation 8, where Ri
is the rate of free radical initiation obtained using the
a-tocopherol analogue 2,2,5,7,8-pentamethyl-6-chromanol
(PMHC) as reference antioxidant for which n = 2.i
D½O2t ¼
kp½RH
kinh
lnð1 t=sÞ (7)
Ri ¼ n½ArOHs (8)
Autoxidation experiments were performed in a two-
channel oxygen-uptake apparatus, based on a Validyne
DP 15 differential pressure transducer, already described
elsewhere (Amorati et al. 2001). The entire apparatus was
immersed in a thermostated bath to ensure a constant
temperature within 0.1°C. In a typical experiment, an
air-saturated solution of styrene or cumene in chloroben-
zene containing AIBN (5 9 102 mol/L) was equilibrated
with the reference solution containing an excess of PMHC
(1 9 103) in the same solvents at 30°C until steady oxy-
gen consumption was detected. A small amount of a con-
centrated solution of antioxidant (about 1 9 103 mol/L)
was injected into both the reference and sample flasks,
and the oxygen consumption in the sample was mea-
sured, after calibration of the apparatus, from the differ-
ential pressure recorded with time between the two
channels.
Determination of Ab1-42 oligomer-induced
intracellular ROS formation
The intracellular hydrogen peroxide and superoxide anion
formation induced by Ab1-42 oligomer at SH-SY5Y cell
level was determined using, respectively, the probe
2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA,
kexc = 485 nm, kem = 535 nm), and dihydroethidium
(DHE, kexc = 380 nm, kem = 445 nm). SH-SY5Y cells
were cultured in BD FalconTM 8-well Culture slides (sur-
face area 0.7 cm2/well) at 1 9 104 cells/well for 24 h. The
cells were then treated for 3 h with various concentrations
of compounds (3–30 lmol/L) at 37°C prior to the treat-
ment of 3 h with Ab1-42 oligomer (5 lmol/L). At the end
of treatment, the cells were washed and incubated with
DCFH-DA (5 lmol/L) or DHE (10 lmol/L) for 30 min
in the dark. After removal of the probes, cells were
washed with PBS and incubated with DMEM serum free
for 1 h at 37°C. Intracellular ROS formation was
measured under a fluorescence microscope (Zeiss Axio
Imager M1). Fluorescence images were captured with an
AxioVision image recording system computer. Four ran-
domly selected areas with 50–100 cells in each were ana-
lyzed and the values obtained are expressed as fold
increases in hydrogen peroxide and superoxide anion ver-
sus untreated cells.
Determination of tert-butyl hydroperoxide-
induced intracellular ROS formation
As above, the intracellular hydrogen peroxide and super-
oxide anion formation induced by tert-butyl hydroperoxide
(t-BuOOH) at SH-SY5Y cell level was determined using,
respectively, the probes DCFH-DA and DHE. Briefly, SH-
SY5Y cells were cultured in 96-well microtiter plates at
3 9 104 cells/well for 24 h. The medium was then
removed and the cells were treated for 3 h with various
concentrations of compounds (3–30 lmol/L) at 37°C.
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After treatment, the cells were washed with PBS and then
incubated with DCFH-DA (5 lmol/L) or DHE (10 lmol/
L) in PBS at 37°C in 5% CO2 for 30 min. After removal
of the probes and further washing, the cells were incu-
bated with t-BuOOH (50 lmol/L) in PBS for 30 min. At
the end of incubation, the green or red fluorescence of
the cells from each well was measured with a spectrofluo-
rometer (TECAN, GENios). The results are expressed as
fold increases in intracellular ROS evoked by exposure to
t-BuOOH.
Determination of total antioxidant activity
in membrane and cytosolic fractions
To determine whether AP2469 exerts its antioxidant
activity mainly in the membrane or cytosolic fraction,
TAA was measured on both the cytosolic and membrane
enriched fractions as previously reported (Tarozzi et al.
2012). Briefly, SH-SY5Y cells were cultured in cultures
dishes at 4 9 106 cells/dish for 24 h. After incubation,
the SH-SY5Y cells were treated for 2 h with various con-
centrations of AP2469 (3–30 lmol/L). The SH-SY5Y cells
were then washed three times with cold PBS, collected in
1 mL of PBS and centrifuged for 10 min at 10,000 rpm
at 4°C. The supernatant obtained was removed and the
cells were washed with 1 mL of PBS. This was repeated
twice more, and the pellet was finally reconstituted in
600 lL of 0.05% Triton X-100. Cells were then homoge-
nized and allowed to stand at 4°C for 30 min. Cytosolic
and membrane enriched fractions were subsequently sepa-
rated by centrifugation at 14,000 rpm for 15 min at 4°C.
TAA in cell fractions was determined by the decoloration
of the radical cation of 2,2′-azinobis-(3-ethylbenzothiazo-
line-6-sulfonic acid) (ABTS•+), in terms of quenching of
absorbance at 740 nm. Values obtained for each sample
were compared with the concentration–response curve of
a standard antioxidant, such as Trolox (a water-soluble
vitamin E analogue), and the results are expressed as
lmol of Trolox Equivalent Antioxidant Activity per mg
of protein (TEAA lmol/mg protein).
Determination of Ab1-42 oligomer-induced nitric
oxide and tumor necrosis factor alpha release
THP-1 cells were seeded in 96-well plates at
5 9 104 cells/well for 24 h. At the end of incubation, the
medium was changed with a fresh one with AP2469
30 lmol/L for 3 h. The cells were then washed with PBS
and incubated for a further 12 h with Ab1-42 oligomer
(5 lmol/L). The content of each well was then removed
and centrifuged at 2500g for 10 min, and the supernatant
was frozen at 20°C for the subsequent analysis of
released NO and tumor necrosis factor alpha (TNFa). To
determine the NO levels, 100 lL of supernatant was incu-
bated with 100 lL of Griess reagent (Sigma Aldrich) in
the dark at room temperature for 15 min. The intensity
of the color that developed was then measured at 540 nm
using a spectrophotometer (TECAN, GENios). Values
are reported as percent increases in treated cells versus
untreated cells. The TNFa levels in 100 lL of supernatant
were determined by Ray Bio ELISA kit according to the
manufacturer’s instructions (Ray Biotech, Inc., GA). The
concentration of TNFa levels was calculated from a TNFa
standard curve standard of 25–6000 pg/mL and the values
are reported as percent increases in treated cells versus
untreated cells.
Statistical analysis
Data are reported as mean  SD of at least three inde-
pendent experiments. Statistical analysis was performed
using one-way ANOVA with Dunnett post hoc test and
Student’s t-test, as appropriate. Differences were consid-
ered significant at P < 0.05. Analyses were performed
using GraphPad Prism 4.0 software.
Results
Effects of AP2469 on cholinesterase
and BACE1 activity, and Ab1-42 aggregation
The substitution of the 5,6-dimethoxycoumarin nucleus
of AP2238 and AP2243 with the catecholic one reduced
the anti-AChE activity by two orders of magnitude
(Table 1).
Regarding BACE1 inhibition, AP2469 showed an IC50
value of 6.5 lmol/L (Table 1).
As previously reported, AP2238 and AP2243 act as weak
inhibitors of hAChE-induced amyloid aggregation (35%
and 38%, respectively, at 100 lmol/L concentration, Piazzi
et al. 2003, 2007), while they do not show any significant
inhibitory activity against amyloid self-aggregation. On the
other hand, co-incubation of Ab1-42 with increasing con-
centrations of AP2469 led to a concentration-dependent
reduction in amyloid fibrillization as demonstrated by a
ThT-based assay (Table 1).
Effects of AP2469 on Ab1-42 oligomer-
and Ab25-35-induced neurotoxicity
The ability of AP2469 to interfere with the aggregation
processes of Ab1-42 makes this compound eligible for
further neuroprotection experiments with human neuro-
nal SH-SY5Y and monocytic THP-1 cell cultures. The
SH-SY5Y and THP-1 cells were treated for 3 h with vari-
ous concentrations, not associated with toxicity, of
2014 | Vol. 2 | Iss. 2 | e00023
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AP2469, AP2243, and galantamine (1–30 lmol/L) in the
presence or absence of Ab1-42 oligomers (5 lmol/L). The
same experiments were also performed with Ab25-35
(5 lmol/L), a short peptide generated by proteolysis of
Ab1-40 with neurotoxic and aggregation properties similar
to Ab1-42 (Tarozzi et al. 2010a,b). Cell toxicity induced by
both Ab1-42 oligomers and Ab25-35, in terms of mitochon-
drial activity loss, was then evaluated by the reduction in
MTT to formazan. The treatment of SH-SY5Y cells with
AP2469, galantamine, but not AP2243, led to a decrease
in cytotoxicity elicited by Ab1-42 oligomers (Table 1). As
shown in Figure 2A, the observed decrease in toxicity
was dose-dependent and significant for 10 lmol/L and
30 lmol/L of both AP2469 and galantamine. In particu-
lar, AP2469 showed a higher neuroprotective effect than
galantamine at 30 lmol/L (toxicity inhibition, 93% vs.
58%). In contrast to AP2243 and galantamine, AP2469
also showed the ability to inhibit the Ab1-42 oligomer-
induced cytotoxicity in THP-1 cells at 10 lmol/L and
30 lmol/L (Fig. 2B). Similar neuroprotective effects of
compounds studied were recorded against Ab25-35-
induced toxicity in both SH-SY5Y and THP-1 cells
(Fig. 3A and B).
Effects of AP2469 on Ab1-42 oligomer-
binding to plasma membrane and
subsequent intracellular ROS formation
The binding of Ab1-42 oligomers (5 lmol/L) with both
SH-SY5Y and THP-1 cells obtained in 30 min was signifi-
cantly reduced by cotreatment of AP2469, as determined
by the CR assay (Fig. 4). In the same experimental condi-
tions, the cotreatment with AP2243 did not modify the
binding of Ab1-42 oligomers with both cell types (data not
shown).
Table 1. Inhibitory activities on human AChE and BuChE, BACE1, Ab1-42 self-aggregation, Ab1-42 oligomer cytotoxicity of the studied com-
pounds.
Compounds
IC50 lmol/L  SEM1
hAChE hBuChE BACE1 Ab1-42 self-aggregation
Ab1-42 oligomer toxicity
SH-SY5Y cells THP-1 cells
AP2238 0.044  0.0062 48.9  3.72  ≫503 – –
AP2243 0.018  0.0034 118  163 0.24  0.03 ≫503 ≫303 ≫303
AP2469 8.60  0.21 124  13 6.49  0.31 21.7  3.4 7.50  0.72 8.18  0.51
Galantamine 2.01  0.15 20.7  1.5 >53,5 ≫503 7.99  0.91 ≫303
1Concentration of compound resulting in 50% inhibition of human AChE, BuChE, BACE1 activity, Ab1-42 self-aggregation, and Ab1-42 oligomer
cytotoxicity.
2From Piazzi et al. 2003.
3Not active at the highest tested concentration (50 lmol/L, 30 lmol/L or 5 lmol/L).
4From Piazzi et al. 2007.
5From Mancini et al. 2007.
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Figure 2. Effects of compounds AP2469, AP2243 and galantamine
on Ab1-42 oligomer-induced cytotoxicity in SH-SY5Y (A) and THP-1 (B)
cells. The cell viability in SH-SY5Y and THP-1 cells was determined by
MTT assay (as described in the Materials and Methods section), after
3 h of incubation with Ab1-42 oligomers (5 lmol/L) in the presence or
absence of various concentrations of compounds (1–30 lmol/L). The
results are expressed as a percentage of control cells and the values
are reported as mean  SD of three independent experiments
(*P < 0.05, **P < 0.01 vs. untreated cells at ANOVA with Dunnett
post hoc test).
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Antioxidant activity of AP2469
We evaluated the ability of AP2469 and AP2243 to coun-
teract the peroxyl radicals by EPR spectroscopy. The
results clearly showed that the presence of the di-hydroxy
moiety dramatically increased the radical trapping ability
of AP2469 compared to AP2243 (Table 2). In addition,
these results are confirmed by a decrease in O2 consump-
tion induced by reaction with AIBN and styrene in the
presence of AP2469 (Fig. 5A).
The rate of reaction of AP2469 with peroxyl radicals
was about threefold greater than that recorded for cate-
chol or quercetin under identical experimental settings,
indicating that AP2469 forms a phenoxyl (ortho-semiqui-
none) radical stabilized by resonance on the conjugated
double bonds of the stilbene skeleton (Fig. 5B). The num-
ber of peroxyl radicals trapped by each AP2469 molecule
(the stoichiometric factor, n) was approximately two,
similar to that of other catecholic antioxidants, which are
known to be oxidized to the corresponding ortho-
quinone (Amorati et al. 2006; Valgimigli and Pratt 2012).
Then we also evaluated the ability of AP2469 and
AP2243 to counteract intracellular ROS formation, such
as hydrogen peroxide and superoxide anion, evoked by
Ab1-42 oligomers (5 lmol/L) in SH-SY5Y cells using
DCFH-DA and DHE assays, respectively. The ROS forma-
tion has been directly related to membrane and cytoplasm
perturbation by soluble oligomers (Glabe 2006; Rauk
2008). As shown in Figure 6, AP2469 significantly inhib-
ited the Ab1-42 oligomer-induced hydrogen peroxide and
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Figure 3. Effects of compounds AP2469, AP2243 and galantamine
on Ab25-35-induced cytotoxicity in SH-SY5Y (A) and THP-1 (B) cells.
The cell viability in SH-SY5Y and THP-1 cells was determined by MTT
assay (as described in the Materials and Methods section), after 3 h
of incubation with Ab25-35 (5 lmol/L) in the presence or absence of
various concentrations of compounds (1–30 lmol/L). The results are
expressed as a percentage of control cells and the values are reported
as mean  SD of three independent experiments (*P < 0.05,
**P < 0.01 vs. untreated cells at ANOVA with Dunnett post hoc test).
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Figure 4. Effects of compounds AP2469 on the binding of Ab1-42
oligomers with SH-SY5Y (A) and THP-1 (B) cells. SH-SY5Y and THP-1
cells were treated with Ab1-42 oligomers (5 lmol/L) for 30 min in the
presence or absence of compound AP2469 (30 lmol/L). At the end of
incubation, the Ab1-42 oligomer binding to plasma membrane was
determined by CR assay (as described in the Materials and Methods
section) and the results are expressed as a percentage of control cells.
The values are reported as mean  SD of three independent
experiments (°°P < 0.01 vs. untreated cells and *P < 0.05 vs. treated
cells with Ab1-42 oligomers at Student’s t-test).
Table 2. Intrinsic antioxidant activity of AP2469, AP2243, and of
other reference phenolic antioxidants.
Compounds kROO (mol/L
1sec1)1 n2
AP2469 (1.6  0.2) 9 106 1.9  0.2
AP2243 <103 –3
Catechol (5.5  0.5) 9 105 2.0  0.2
Quercetin (5.6  0.5) 9 105 2.1  0.2
1Rate constant for the reaction with peroxyl radicals.
2Number of radicals trapped by each antioxidant molecule.
3Not determined.
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superoxide anion formation at all used concentrations
(3–30 lmol/L). In parallel, we also investigated the
antioxidant activity of AP2469 and AP2243 against the
t-BuOOH-induced ROS formation, in SH-SY5Y using
same assays. t-BuOOH is an organic peroxide that gener-
ates a pattern of ROS similar to that involved in the oxi-
dative stress induced by Ab Rauk 2008). Remarkably,
pretreatment of both the cell types with AP2469, but not
AP2243, at all selected concentrations (3–30 lmol/L)
significantly reduced the ROS formation induced by
t-BuOOH at 50 lmol/L (Figure 7).
In order to better evaluate the ability of AP2469 to
exert its antioxidant activity in SH-SY5Y cells, and to
obtain an indirect evaluation of the cellular bioavailability
of AP2469, we measured the total antioxidant activity
(TAA) of cytosolic and membrane enriched fractions of
SH-SY5Y cells treated with the compound. As reported in
Figure 8, both the membrane and cytosolic fractions
obtained from SH-SY5Y cells treated for 2 h with AP2469
showed a significant increase in TAA in comparison to
untreated cells. A significant TAA increase was found at
cytosolic level with all AP2469 tested concentrations
(3–30 lmol/L), while, at membrane levels, the TAA
increase was significant only at the highest tested concen-
tration (30 lmol/L).
Effects of AP2469 on Ab1-42 oligomer-
induced NO and TNFa release
Ab1-42 oligomers are known to increase levels of inducible
nitric oxide synthase (iNOS) in microglial cells with gial
activation and release of proinflammatory cytokines
(Dheen et al. 2005; Ajit et al. 2009). As the induction of
iNOS is associated with increased production of NO, we
examined the effects of AP2469 30 lmol/L on production
of NO using Griess reagent. We found that cotreatment
of THP-1 cells with AP2469 reduced Ab1-42 oligomer-
induced NO release (Fig. 9A). In parallel, the same treat-
ment inhibited the TNFa release from THP-1 cells
(Fig. 9B).
(B)
(A)
Figure 5. (A) Effects of compounds AP2469 and AP2243 on O2 consumption induced by reaction with AIBN and styrene. Oxygen consumption
observed during the AIBN (0.05 mol/L)-initiated autoxidation of styrene (4.3 mol/L) at 30°C in chlorobenzene without inhibitors (trace a) or in the
presence of 6.5 lmol/L of: AP2243 (b); catechol (c); quercetin (d), AP2469 (e); PMHC (f). (B) Proposed antioxidant action of AP2469.
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Discussion
AD’s multifactorial origin has stimulated the recent thera-
peutic approach in which drug candidates are designed to
possess different pharmacological properties and act on
multiple targets.
In light of the development of a new multifunctional
compound with a broader spectrum of action, we
hypothesized that the simple structural modification of
the dimethoxycoumarin nucleus of AP2243 to give a cate-
chol-bearing derivative could lead to a new compound
endowed with both anticholinesterase and antiaggregating
properties, together with antioxidant, neuroprotective,
anti-inflammatory activity at neuronal and microglial cell
level.
The substitution of the 5,6-dimethoxycoumarin nucleus
of AP2238 and AP2243 with the catecholic one reduced
the anti-AChE activity by two orders of magnitude, thus
underlying the importance of the dimethoxycoumarin
fragment for optimal anticholinesterase activity. Neverthe-
less, in light of a balanced inhibition profile, a partial loss
of the inhibitory potency against one target is acceptable
if other pharmacological properties are gained and can be
simultaneously exerted. Moreover, an IC50 value in the
micromolar range, as for AP2469, is likely suitable to ele-
vate the cholinergic tone as demonstrated by the clinical
use of the natural alkaloid galantamine, an AChE-selective
inhibitor with a micromolar inhibitory potency. Like gal-
antamine, AP2469 is a selective AChE inhibitor even if
selectivity is reduced by one order of magnitude with
respect to AP2243 and AP2238.
On the basis of the inhibitory activity of quercetin
against BACE1 activity in both a cell-free system and in
neuronal cells (Shimmyo et al. 2008) the ability of
AP2469 was investigated. Regarding BACE1 inhibition,
AP2469 showed a potency of one order of magnitude
lower than that of AP2243, but exhibited a BACE1 inhibi-
tory activity very similar to that found for other nonpep-
tidic inhibitors such as the noncompetitive BACE1
inhibitor bis(7)-tacrine (7.5 lmol/L, Fu et al. 2008) or
the catechol derivative quercetin (5.4 lmol/L, Shimmyo
et al. 2008).
As previously reported, AP2238 and AP2243 act as
weak inhibitors of hAChE-induced amyloid aggregation
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Figure 6. Effects of compounds AP2469 and AP2243 on Ab1-42 oligomer-induced ROS formation in SH-SY5Y cells. (A) SH-SY5Y cells were
treated for 3 h with various concentrations of compound AP2469 (3–30 lmol/L) prior to the treatment of 3 h with Ab1-42 oligomer (5 lmol/L).
At the end of incubation, hydrogen peroxide and superoxide anion formation was determined using, respectively, the probe, DCFH-DA and DHE,
as described in the Materials and Methods section. Four randomly selected areas with 50–100 cells in each were analyzed under a fluorescence
microscope and the values obtained are expressed as fold increases in ROS formation induced by exposure to Ab1-42 oligomers. The values are
shown as mean  SD of three independent experiments (*P < 0.05, **P < 0.01 vs. untreated cells at Student’s t-test). Representative images of
hydrogen peroxide (B) and superoxide anion (C) formation. Scale bars: 100 lm.
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(Piazzi et al. 2003, 2007) while they do not show any sig-
nificant inhibitory activity against amyloid self-aggrega-
tion. Due to this weak activity profile of both previously
published compounds and the lower inhibitory activity of
AP2469 on hAChE, AChE-induced amyloid aggregation
was not considered a potential target of action for
AP2469.
On the other hand, AP2469 is able to interfere with
Ab42 oligomerization in a concentration-dependent
manner.
The ability of AP2469 to interfere with the aggregation
processes of Ab1-42 makes this compound eligible for fur-
ther neuroprotection experiments with SH-SY5Y and
THP-1 cell cultures. The treatment of SH-SY5Y cells with
AP2469 and galantamine, but not AP2243, led to a
dose-dependent decrease in cytotoxicity elicited by both
Ab1-42 oligomers and Ab25-35 peptide. Similarly, treatment
with AP2469, but not galantamine or AP2243, showed
significant inhibitor effects on Ab-induced toxicity in
THP-1 cells.
The AP2469 neuroprotective effect findings prompted
us to evaluate its ability to prevent the binding between
Ab1-42 oligomer and the plasma membrane surface, an
action that triggers irreversible membrane alterations and
initiates a sequence of pathological events leading to cell
dysfunction and death. The binding of Ab1-42 oligomers
with both SH-SY5Y and THP-1 cells was significantly
reduced by cotreatment of AP2469. In the same experi-
mental conditions, the cotreatment with AP2243 did not
modify the binding of Ab1-42 oligomers with both cell
types. These results show that AP2469 and galantamine
afford cytoprotection through mechanisms that are likely
unrelated to AChE inhibition (e.g., AP2243 inhibits the
AChE activity, but not Ab-induced cytotoxicity). The
ability of galantamine to exert the cytoprotective effects in
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Figure 7. Effects of compounds AP2469 and AP2243 on t-BuOOH-
induced ROS formation in SH-SY5Y cells. SH-SY5Y cells were treated
for 3 h with various concentrations of AP2469 and AP2243 (3–
30 lmol/L) prior to the treatment of 30 min with t-BuOOH (50 lmol/
L). At the end of incubation, hydrogen peroxide and superoxide anion
formation was determined using, respectively, the probe, DCFH-DA
and DHE (as described in the Materials and Methods section). The
results are expressed as fold increases in ROS formation induced by
exposure to t-BuOOH and the values are reported as mean  SD of
three independent experiments (*P < 0.05, **P < 0.01 vs. untreated
cells at ANOVA with Dunnett post hoc test).
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Figure 8. Total antioxidant activity of membrane and cytosolic
fraction from SH-SY5Y cells treated with AP2469. SH-SY5Y cells were
treated for 2 h with various concentrations of AP2469 (3–30 lmol/L),
and cytosolic and membrane fractions were separated. Both cellular
fractions were submitted to the ABTS radical cation decolorization
assay (as described in the Materials and Methods section). The results
are expressed as lmol of TEAA per mg of protein and the values are
shown as mean  SD of three independent experiments (*P < 0.05,
**P < 0.01 vs. untreated cells at ANOVA with Dunnett post hoc test).
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SH-SY5Y cells is confirmed by other studies that linked
these effects with the agonist action of galantamine on
nicotinic receptors (Arias et al. 2005). In contrast to gal-
antamine, the cytoprotective effects of AP2469 in both
SH-SY5Y and THP-1 cells could be attributed to inhibi-
tory effects on early pathological events leading to cell
death, such as Ab1-42 oligomer-binding to plasma mem-
brane and subsequent toxicity. Interestingly, the ability of
AP2469 to exert the neuroprotective effects observed in
neuronal SH-SY5Y cells also in microglial-like THP-1
cells suggests that this compound could preserve the neu-
roprotective effects of microglial activation, such as
phagocytosis of dead neurons and clearance of debris
(Polazzi and Monti 2010).
Regarding this evidence, it is plausible that AP2469
interacts directly with specific amino acids present in the
Ab peptide. In contrast to AP2243, AP2469 has a
di-hydroxy moiety which could form hydrogen bonds
with acceptor groups of amino acid residues in Ab pep-
tide (i.e., Ile31, Ile32 and Met35) that are critical for its
aggregation and subsequent cytotoxicity (Pike et al. 1995;
Clementi et al. 2005).
Finally, the promising results obtained on THP-1 cell
plasma membranes prompted us to evaluate the anti-
inflammatory effects of AP2469 in terms of prevention of
glial activation. Ab1-42 oligomers are known to increase
levels of inducible nitric oxide synthase (iNOS) in
microglial cells with glial activation and release of proin-
flammatory cytokines (Dheen et al. 2005; Ajit et al.
2009). As the induction of iNOS is associated with
increased production of NO, we next examined the effects
of AP2469 on production of NO. We found that cotreat-
ment of THP-1 cells with AP2469 reduced Ab1-42 oligo-
mer-induced NO release. In parallel, the same treatment
inhibited the TNFa release from THP-1 cells.
The ability of AP2469 to modulate the THP-1 cells’
proinflammatory effects induced by Ab1-42 oligomers is
particularly significant, as microglial cells can play an
important role in the activation of neuroinflammation,
which has been linked to the neuronal death associated
with AD (Glass et al. 2010).
Integrated studies of antioxidant activity clearly showed
that the presence of the catechol moiety also dramatically
increased the radical trapping ability of AP2469 compared
to AP2243, and reduced the intracellular formation of
hydrogen peroxide and superoxide anion induced by both
Ab1-42 oligomers and t-BuOOH in SH-SY5Y cells. Taken
together, these data highlight the very good chain-breaking
antioxidant performance of AP2469 and its potential in
counteracting oxidative damage at neuron level involved
in AD pathogenesis and progression. In this regard, recent
studies have suggested that Ab1-42 as small oligomers can
insert themselves into the lipid bilayer and initiate lipid
peroxidation and, consequently, oxidative damage to pro-
teins and other biomolecules (Butterfield et al. 2001; But-
terfield and Sultana 2011). Therefore, it is also probable
that the antioxidant effects observed after pretreatment of
SH-SY5Y with AP2469 is ascribed to its ability: (1) to
spread into the membrane and to form a barrier on the
membrane through the formation of hydrogen bonds with
the polar head groups at the lipid–water interface of the
plasma membrane and protect it from external prooxidant
aggressors including Ab peptides; (2) to prevent the for-
mation of sulfuranyl radicals from one electron oxidation
of Met35 present in Ab1-42, which can then initiate the
process of lipid peroxidation (Butterfield and Sultana
2011); (3) to enter into the cytoplasm and to exert the
antioxidant activity at this level. The ability of AP2469 to
cross the cytoplasmatic membrane and to reach the cyto-
plasm of SH-SY5Y cells suggests a favorable pharmacoki-
netic profile of this molecule. As final targets are located
in the CNS, the possibility for AP2469 to penetrate the
blood–brain barrier (BBB) was also estimated by calculat-
ing physico-chemical properties, known to influence BBB
penetration. In particular, with a log P value of 4.60,
AP2649 is significantly more lipophilic than catechol
(log P = 1.09) and quercetin (log P = 0.35). With a num-
ber of hydrogen bond donors ≤3 (n. H-bond donor = 2),
hydrogen bond acceptor largely ≤7 (n. H-bond accep-
tor = 3), and molecular weight close to 400 g/mol
(401.45 g/mol), the physico-chemical property profile of
AP2469 is in compliance with Lipinski’s and Wenlock’s
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Figure 9. Compound AP2469 inhibits Ab1-42 oligomer-induced NO
(A) and TNFa (B) release in THP-1 cells. THP-1 cells were treated for
3 h with compound AP2469 (30 lmol/L) prior to the treatment for
12 h with Ab1-42 oligomer (5 lmol/L). At the end of incubation, NO
and IL-1 release was estimated using the Griess reagent and Ray Bio
ELISA kit, respectively (as described in the Materials and Methods
section). The results are expressed as a percentage of control cells and
the values are reported as mean  SD of three independent
experiments (°°P < 0.01 vs. untreated cells and *P < 0.05 vs. treated
cells with Ab1-42 oligomers at Student’s t-test).
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guidelines for good passive CNS penetration (Wenlock
et al. 2003; Pajouhesh and Lenz 2005).
In conclusion, starting from the first dual binding site
AChE inhibitor AP2238, with a simple structural modifi-
cation, we were able to obtain a multi-target ligand.
Indeed, we followed the new medicinal chemistry para-
digm which states that, in order to significantly modify
the progression of a multifactorial disease such as AD, the
modulation of the activity of a single-protein target may
not be appropriate. Therefore, with the introduction of a
catechol moiety, we obtained AP2469 that possesses anti-
AChE and anti-BACE1 activities, and shows an enlarged
activity profile able to interact with other key targets for
AD. Specifically, the combined neuroprotective and anti-
inflammatory properties and its potential in counteracting
oxidative damage in both neuron and microglial cells
make AP2469 a potential drug candidate able to modify
the course of the disease.
Disclosure
None declared.
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